When should the seminal vesicles be included in the target volume in prostate radiotherapy?

2.50
Hdl Handle:
http://hdl.handle.net/10541/70239
Title:
When should the seminal vesicles be included in the target volume in prostate radiotherapy?
Authors:
Bayman, Neil A ( 0000-0002-9756-8676 ) ; Wylie, James P
Abstract:
External beam radiotherapy to the prostate and seminal vesicles as a radical treatment for prostate cancer can result in a significant dose being delivered to the rectum. This can be reduced if the target volume includes the prostate only. Using a Medline search, published studies are reviewed to show that the risk of seminal vesicle involvement can be accurately predicted using readily available pre-treatment parameters. We recommend when to exclude the seminal vesicles from a target volume, and the proportion of seminal vesicles that should be included in a target volume in higher risk patients.
Affiliation:
Department of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK. neil.bayman@christie-tr.nwest.nhs.uk
Citation:
When should the seminal vesicles be included in the target volume in prostate radiotherapy? 2007, 19 (5):302-7 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
Jun-2007
URI:
http://hdl.handle.net/10541/70239
DOI:
10.1016/j.clon.2007.03.005
PubMed ID:
17448647
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBayman, Neil A-
dc.contributor.authorWylie, James P-
dc.date.accessioned2009-06-11T16:04:25Z-
dc.date.available2009-06-11T16:04:25Z-
dc.date.issued2007-06-
dc.identifier.citationWhen should the seminal vesicles be included in the target volume in prostate radiotherapy? 2007, 19 (5):302-7 Clin Oncolen
dc.identifier.issn0936-6555-
dc.identifier.pmid17448647-
dc.identifier.doi10.1016/j.clon.2007.03.005-
dc.identifier.urihttp://hdl.handle.net/10541/70239-
dc.description.abstractExternal beam radiotherapy to the prostate and seminal vesicles as a radical treatment for prostate cancer can result in a significant dose being delivered to the rectum. This can be reduced if the target volume includes the prostate only. Using a Medline search, published studies are reviewed to show that the risk of seminal vesicle involvement can be accurately predicted using readily available pre-treatment parameters. We recommend when to exclude the seminal vesicles from a target volume, and the proportion of seminal vesicles that should be included in a target volume in higher risk patients.en
dc.language.isoenen
dc.subjectCancer Invasivenessen
dc.subjectCancer Stagingen
dc.subjectProstate Canceren
dc.subject.meshBiopsy-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNeoplasm Invasiveness-
dc.subject.meshNeoplasm Staging-
dc.subject.meshProstate-Specific Antigen-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshRadiation Injuries-
dc.subject.meshRadiotherapy Dosage-
dc.subject.meshRadiotherapy Planning, Computer-Assisted-
dc.subject.meshRadiotherapy, Conformal-
dc.subject.meshRectum-
dc.subject.meshRisk-
dc.subject.meshSeminal Vesicles-
dc.titleWhen should the seminal vesicles be included in the target volume in prostate radiotherapy?en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK. neil.bayman@christie-tr.nwest.nhs.uken
dc.identifier.journalClinical Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.